Press Releases

Read Regulatory and non-regulatory press releases

  • All
  • Non-Regulatory
  • Regulatory

MPI’s spinout Oncology Venture announces positive interim results from a Phase 1/2 DRP guided study of LiPlaCis in heavily pretreated breast cancer patients

MPI’s spinout Oncology Venture will execute license to multi TKI phase 3 compound

Drug response prediction in high-risk multiple myeloma – prediction of melphalan and bortezomib response.

Result of evaluation of DRP for TKI drug from Big Pharma available third week of January 2018

MPI Announces registration of trademark for DRP

MPI – LiPlaCis Phase 2 Recruitment Ongoing in DRP Screened Breast Cancer Patients: Relevant Clinical Benefits in 3 out of 5 Treated Patients

MPI: MPI publishes Half-year Report for the first half of 2017

MPI: DRP to be evaluated in 6 to 7 prospective studies

MPI: 2X Oncology’s CEO, George O. Elston’s newsletter to shareholders

MPI – Investor Analysis of Oncology Venture Sweden AB

MPI: Artikel om MPI og Oncology Venture i Medwatch

MPI: OV to evaluate the potential of in-licensing a small molecule compound for development in cancer from a major Pharmaceutical company

MPI – Last day of trading in paid subscription shares

MPI: Oncology Venture and Eisai Forge Exclusive Global License Agreement for Clinical Stage Oncology Drug PARP Inhibitor E7449 – 2X-121

MPI raised SEK 10,3 million in rights issue

Cancer response to OV’s LiPlaCis successfully predicted in early data by MPIs DRP technology

Medical Prognosis Institute A/S Announces Start of Subscription Period for Rights Issue

MPI: 2X Oncology Inc. presents at Jefferies Global Healthcare Conference (live webcast)

MPI – OV’s spinout – 2X Oncology Obtains US IND for 2X-111

MPI – The efficacy of chemotherapy with epirubicin, one the of most used drugs in Breast Cancer can now be predicted by DRP – Poster published at ASCO